- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00841867
The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism) (Pilot OGTT)
A Pilot Study Investigating the Effects of Partial Pancreatectomy on Glucose Tolerance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Beta cells of the pancreas are the insulin producing cells. People with impaired fasting glucose have a beta cell mass ~50% of that of normal glucose tolerant subjects.
A 2006 canine study by Dr. Peter Butler's group at UCLA demonstrated that glucose stimulated insulin secretion was deficient after 50% decrease in beta cell mass after distal pancreatectomy compared to those dogs who had sham surgery. The pancreatectomized dogs had impaired fasting glucose with impaired insulin secretion and insulin resistance. The decreased insulin secretion was a result of decreased insulin secretory pulses or bursts with no change seen in pulse frequency, the same pattern seen in humans with Type 2 diabetes. Conclusions derived from this study include the following:
- When beta cell mass declines to ~50% the capacity for the remaining beta cells to secrete insulin in appropriate secretory bursts is compromised, leading to a deficit in insulin secretion most obvious on glucose stimulation.
- The decreased insulin burst mass results in an additional component of insulin resistance, and this together with the compromised capacity for insulin secretion leads to decompensation of glucose regulation and diabetes onset.
How does this translate in humans who have had partial pancreatectomy? In 1990, Kendall and colleagues published a study looking at the effects of hemipancreatectomy in healthy human subjects on insulin secretion and glucose tolerance. These subjects were donors for pancreatic transplantation. They showed that fasting insulin and c-peptide levels were lower one year after hemipancreatectomy. Seven of the 28 donors had abnormal glucose tolerance one year after hemipancreatectomy, but all 28 had normal fasting plasma glucose levels. This study and others like it confirm the development of impaired glucose tolerance after partial pancreatectomy, but pulsatile insulin secretion and hepatic insulin clearance were not measured.
As stated above, the main objective of this pilot study is to establish and quantify the impact of a deficit in beta cell mass, due to partial pancreatectomy for benign tumors, on glucose tolerance. Results of this study may be used to develop a future metabolic study that uses glucose isotopes to establish the effects of partial pancreatectomy on glucose tolerance, basal and stimulated insulin secretion as well as hepatic and extrahepatic insulin sensitivity under conditions of usual physiology. This will enable us to further understand the relationship between loss of beta cells, decreased insulin secretion and increased insulin resistance in humans.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- UCLA General Clinical Research Center (GCRC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and Female subjects
- 18-80 years of age who have had
- partial pancreatectomy due to a benign lesion
- OR are healthy control subjects
- are willing to fast (nothing to eat or drink for 10 hours)prior to visits
Exclusion Criteria:
- Pancreatic malignancy
- Chronic pancreatitis
- Pregnant
- On steroid medications such as prednisone
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
|
All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
|
2
Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
|
All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine differences in glucose metabolism between subjects who have had partial pancreatectomy due to a benign lesion and those who have not had such a surgery.
Time Frame: Outcome will be determined after all data has been collected.
|
Outcome will be determined after all data has been collected.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DK61539
- R01DK061539 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Glucose Tolerance
-
Psychiatric Centre RigshospitaletUniversity of Cambridge; University Hospital, Gentofte, CopenhagenUnknownImpaired Glucose Tolerance Associated With DrugsDenmark
-
Columbia UniversityCompletedBody Weight | Impaired Glucose Tolerance in ObeseUnited States
-
Maastricht University Medical CenterCompletedObesity | Insulin Resistance | Impaired Glucose Tolerance in ObeseNetherlands
-
Wroclaw Medical UniversityCompletedPreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)Poland
-
The University of Texas Health Science Center at...Amylin Pharmaceuticals, LLC.CompletedDiabetes | Impaired Glucose Tolerance (IGT)United States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
University of Oslo School of PharmacyCompletedRenal Transplant Recipients | Posttransplant Diabetes Mellitus | Posttransplant Impaired Glucose ToleranceNorway
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)United States
-
Yonsei UniversityCompletedImpaired Glucose Tolerance | Impaired Fasting Glucose | NormalKorea, Republic of
Clinical Trials on All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
Jaeb Center for Health ResearchRecruitingCystic FibrosisUnited States